Clinical Trial Update: Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating encorafenib in Chinese patients with advanced/metastatic BRAF V600E-mutant solid tumors, including melanoma and non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Encorafenib (encorafenib)

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC | Phase 1 | Status: COMPLETED | Results posted: 2024-06-24